Have any questions? [email protected] +86-21-58998590
Structure search

KIN-8194


CAS No. : 330786-01-1

330786-01-1
Price and Availability of CAS No. : 330786-01-1
Size Price Stock
5mg $320 In-stock
10mg $525 In-stock
25mg $1050 In-stock
50mg $1650 In-stock
100 mg Get quote
200 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-15805
M.Wt: 483.61
Formula: C28H33N7O
Purity: >98 %
Solubility: 10 mM in DMSO
Introduction of 330786-01-1 :

KIN-8194 is an orally active dual inhibitor of HCK and BTK, with IC50 values of 0.915 and <0.495 nM, respectively. KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma (MCL). KIN-8194 overcomes ibrutinib (HY-10997) resistance with a survival benefit in TMD-8 ABC DLBCL xenografted mice[1][2]. In Vitro:KIN-8194 (0-1 μM, 7 days) inhibits the growth of MCL cell lines (Maver-1, JeKo-1, Mino, Rec-1 and Granta-519) and primary cells[1].
KIN-8194 (0-1 μM, 7 days) reduces MCL cell lines proliferation through HCK inhibition[1].
KIN-8194 (100 nM, 6 h) inhibits the AKT-S6 signaling pathway in Maver-1 and Granta-519 cells in an HCK-dependent manner[1].
KIN-8194 (0-1 μM, 30 min) inhibits adhesion of MCL cells ( JeKo-1 and Granta-519) to fibronectin or stromal cells in an HCK-dependent manner[1].
In Vivo:KIN-8194 (12.5-50 mg/kg, p.o., once time) blocks pHCK and pBTK in a dose-dependent manner in MYD88-mutated TMD-8 ABC DLBCL xenograft mouse model[2].
KIN-8194 (50 mg/kg, p.o., daily, 6 weeks) inhibits tumor growth in MYD88-mutated TMD-8 ABC DLBCL xenograft mouse model[2].
KIN-8194 (30 mg/kg, p.o., daily, 22 days) combined with Venetoclax (HY-15531) prolongs the survival of ibrutinib-resistant BTKCys481Ser TMD-8 cells xenograft mice median survival time[2].

Your information is safe with us.